increas confid margin shift toward next gener
product sustain drive strong earn perform
specif research indic benefit posit mix
shift toward high margin next-gener product merial nexgard
merck bravecto zoeti simparica elanco trifexi bayer seresto
sold direct primarili prescript rather over-the-counter
believ next-gener product margin profil
rang versu topic product replac rang
recent conduct price studi variou competitor found
unlik mani offer next-gener
product specif nexgard avail
pertcarerx simpirica avail petcarerx foster
smith addit carri singl sku prescript
flea tick heartworm medic offer broad select
product new product rapidli gain market share
continu limit competit leav compani well
posit gener continu margin improv product gain
experienc gross margin pressur decad
gener basi point margin improv due
posit mix shift next-gener prescript product research
indic product penetr way full near full
penetr opinion continu drive mix shift
result sustain margin improv custom switch older
gener topic product prescript base oral medic also place
busi behind firewal due prescript verif
servic believ continu mix shift result addit upsid
earn surpris expand multipl share
increas ep estim
consensu expect new estim reflect benefit tax reform
per share cash balanc sheet debt strong cash
flow believ could also initi meaning share buy-back offer
sharehold special dividend per share
total debt total asset
continu mix-shift
medic allow sustain strong margin drive
meaning upsid compani share offer much broader
select product competit place busi behind
firewal due prescript verif servic reiter buy rate
share rais price target
import pleas read disclosur disclaim page report
